BlockBeats News, January 1st, one of Neo's two co-founders, Zhang Zhenwen (Erik Zhang), expressed his hope that everyone will refocus on the most important thing for Neo: ongoing construction and long-term development. He is actively promoting the design and research work of Neo 4 to ensure its alignment with the roadmap. At the same time, he is also actively advancing ecosystem development and external cooperation, continuing to focus on application adoption, real-world assets (RWA), stablecoins, and cross-chain interoperability, in order to translate protocol-level improvements into real-world applications and sustainable growth.
Short-term controversies will eventually pass, and what truly determines Neo's future direction is continuous delivery, active collaboration, and real-world applications.
Yesterday, Neo's two co-founders publicly parted ways, with Da Hongfei being accused of not fulfilling financial disclosure commitments, and Zhang Zhenwen being accused of usurping the Foundation's financial authority.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.






Key Takeaways Bybit plans to introduce “MyBank” dollar accounts in partnership with licensed financial institutions, enhancing seamless conversion…









Latest Crypto Market Snapshot as of August 22, 2025 BTC Soars to $115,250.00 ETH Hits $4,450.75 XRP Climbs…

Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.














Key Takeaways Bybit plans to introduce “MyBank” dollar accounts in partnership with licensed financial institutions, enhancing seamless conversion…